Are Analysts Bullish Recro Pharma, Inc. (NASDAQ:REPH) After Last Week?

June 9, 2018 - By Louis Casey

Recro Pharma, Inc. (NASDAQ:REPH) LogoInvestors sentiment increased to 2.37 in 2018 Q1. Its up 0.87, from 1.5 in 2017Q4. It improved, as 5 investors sold Recro Pharma, Inc. shares while 14 reduced holdings. 23 funds opened positions while 22 raised stakes. 10.95 million shares or 14.40% more from 9.57 million shares in 2017Q4 were reported.
Advisory Service Net Limited Liability invested in 555 shares. 4,328 are held by Fincl Bank Of Montreal Can. Parametric Portfolio Assocs Limited holds 20,055 shares. State Bank Of New York Mellon has 53,665 shares. Millennium Mgmt Llc reported 0% in Recro Pharma, Inc. (NASDAQ:REPH). The New York-based Kingdon Mgmt Llc has invested 0.23% in Recro Pharma, Inc. (NASDAQ:REPH). Goldman Sachs Group owns 50,793 shares. Opus Point Partners Limited Liability holds 12,615 shares. Moreover, Barclays Public Limited Company has 0% invested in Recro Pharma, Inc. (NASDAQ:REPH) for 4,974 shares. Prelude Capital Llc stated it has 0.02% in Recro Pharma, Inc. (NASDAQ:REPH). Ny State Common Retirement Fund owns 6,800 shares for 0% of their portfolio. Deutsche Bank Ag reported 0% stake. Balyasny Asset Management Llc has 13,967 shares. Amer Int Group reported 8,708 shares. Wellington Management Grp Inc Inc Llp has invested 0% in Recro Pharma, Inc. (NASDAQ:REPH).

Since December 12, 2017, it had 0 insider buys, and 8 selling transactions for $4.62 million activity. $13,956 worth of stock was sold by SCP Vitalife Partners (Israel) II – L.P. on Thursday, January 4. Broadfin Healthcare Master Fund Ltd also sold $919,128 worth of Recro Pharma, Inc. (NASDAQ:REPH) shares. Berelowitz Michael sold $78,347 worth of stock.

Recro Pharma, Inc. (NASDAQ:REPH) Ratings Coverage

Among 4 analysts covering Recro Pharma (NASDAQ:REPH), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Recro Pharma has $21.2500 highest and $1100 lowest target. $15.81’s average target is 198.87% above currents $5.29 stock price. Recro Pharma had 5 analyst reports since February 13, 2018 according to SRatingsIntel. As per Thursday, April 19, the company rating was initiated by Berenberg. The firm earned “Buy” rating on Tuesday, February 13 by Oppenheimer. The firm has “Buy” rating given on Thursday, May 10 by Oppenheimer. The rating was maintained by Piper Jaffray with “Buy” on Wednesday, February 28. Below is a list of Recro Pharma, Inc. (NASDAQ:REPH) latest ratings and price target changes.

24/05/2018 Broker: Janney Capital Rating: Buy New Target: $11.0000
10/05/2018 Broker: Oppenheimer Rating: Buy New Target: $19.0000 Maintain
19/04/2018 Broker: Berenberg Rating: Buy New Target: $21.2500 Initiate
28/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $12.0 Maintain
13/02/2018 Broker: Oppenheimer Rating: Buy New Target: $19.0 Initiate

The stock decreased 0.19% or $0.01 during the last trading session, reaching $5.29. About 251,910 shares traded. Recro Pharma, Inc. (NASDAQ:REPH) has declined 32.73% since June 9, 2017 and is downtrending. It has underperformed by 45.30% the S&P500.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company has market cap of $108.49 million. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. It currently has negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

More notable recent Recro Pharma, Inc. (NASDAQ:REPH) news were published by: which released: “Pre-Open Movers 05/24: (BW) (SMRT) (WSM) Higher; (REPH) (QUIK) (MLNT) Lower (more…)” on May 24, 2018, also with their article: “REPH INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Recro Pharma, Inc …” published on June 01, 2018, published: “Recro Pharma: Oversold?” on May 26, 2018. More interesting news about Recro Pharma, Inc. (NASDAQ:REPH) were released by: and their article: “Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Recro Pharma, Inc …” published on June 06, 2018 as well as‘s news article titled: “Key events next week – healthcare” with publication date: May 18, 2018.

Recro Pharma, Inc. (NASDAQ:REPH) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: